Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PhRMA Urges Antitrust Exemption For Bioterrorism Research

Executive Summary

An antitrust exemption to allow pharmaceutical companies to share production techniques for bioterrorism countermeasures will speed development of necessary agents, the Pharmaceutical Research & Manufacturers of America says

You may also be interested in...

BioShield Funding: Aventis Prefers Production Deals, Not R&D Support

Aventis-Pasteur would prefer a guaranteed manufacturing agreement rather than incremental payments for bioterrorism countermeasures developed under "Project BioShield.

BioShield Should Extend Liability Protection To Unapproved Products – BIO

Liability protections under "Project BioShield" should be extended to companies that make unapproved bioterrorism countermeasures available in an emergency situation, the Biotechnology Industry Organization said

“Project BioShield”: Industry Has Concerns, FDA Offers Support

A "Project BioShield" provision that would allow government funding only for bioterrorism countermeasures for which no commercial market exists is understood to be a concern among pharmaceutical and biotech companies

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts